secwatch.observer — SEC 8-K summary
======================================

Issuer:     HARROW, INC. (HROW)
CIK:        0001360214
Form:       8-K
Filed at:   2024-02-15T23:59:59+00:00
Accession:  0001493152-24-006873
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Harrow licenses Canadian rights to five ophthalmic products to Apotex; eligible for milestone payments and royalties
--------------------------------------------------------------------------------

- Apotex gets exclusive Canadian rights to VERKAZIA and Cationorm PLUS; will pursue approval for VEVYE, IHEEZO, and ZERVIATE.
- Harrow eligible for milestone payments tied to manufacturing, regulatory approval, and commercial milestones plus royalties on net sales.
- Apotex is Canada's largest pharmaceutical company, with a track record in eyecare.
- Deal covers both prescription (VERKAZIA) and OTC (Cationorm PLUS) products, expanding Harrow's reach into Canada.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1360214/000149315224006873/0001493152-24-006873-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1360214/000149315224006873/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-006873

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer